An international working group is proposing a new way to define Parkinson's disease based on biomarkers (specifically, the protein alpha-synuclein), a system which they believe can accelerate drug development. "We recognize that a biological definition for Parkinson's disease and dementia with Lewy bodies is a major shift," the authors wrote in the position paper. #healthcare #biotech #precisionmedicine https://lnkd.in/gCDF6m3t via GenomeWeb